LASA Annual Conference 2022
LASA will be holding its Annual Conference as a face-to-face meeting on the 22nd and 23rd November. Please save the dates!
As we learn to live with the challenges associated with the COVID pandemic, and following feedback from their members, they have opted for an in-person event, scaled back in size compared to previous years, but with the same excellence for promoting best animal science and welfare in our community. The meeting will be an excellent opportunity to meet with new and old colleagues and importantly, to catch up with trade and industry to continue supporting innovation in laboratory animal science.
They would like to invite all members and non-members to register for the meeting. An interesting and informative scientific program has been created with the excellent support of the LASA Section Conveners including topics and state of the art lectures on innovations in Animal Care & Welfare, Breeding and Husbandry, Training and Education, 3Rs and discussions on Regulatory and Policy frameworks. They are also very excited to announce their two keynote speakers who will provide an excellent framework on the animal translational research and discovery.
Opening Keynote Speaker – Neurotechnology to unravel the function of sensory circuits in the mouse brain – from behaviour in social housing to synchrotron x-ray imaging
Professor Andreas Schaefer is Principal Group Leader of the Sensory Circuits and Neurotechnology Lab and Assistant Research Director at the Francis Crick Institute and a Professor of Neuroscience at the Department of Neuroscience, Physiology and Pharmacology, University College London. Andreas will discussed the innovative behaviour and neurotechnology approaches his groups has developed using laboratory mice to uncover the hidden mechanism of sensory circuits. https://www.crick.ac.uk/research/labs/andreas‐schaefer
Closing Keynote Speaker- Antibody Discovery: Past – Present – Future.
Dr Ruud de Wildt, Director, heading up Antibody Discovery in Biopharm in GSK. His teams have delivered many therapeutic candidate molecules across several therapeutic areas including oncology, immunological and infectious diseases. This includes GSK’s CD-96, ICOS antibodies and a long acting IL-5 antibody, which are currently in late stage clinical studies. In this role, he is responsible for the early stage Biopharm pipeline for GSK. His team uses in-vitro and in-vivo Antibody Discovery processes for discovery and optimization of mAbs and bi-specific antibodies.
We are also looking forward to welcoming our trade and industry colleagues to continue strengthening our partnership, as a key axis of our community. Of course, the key strength of LASA relies on our members, thus our goal is to ensure a collegial and welcoming event for members to Connect –Engage – Explore – Learn – Collaborate and Lead with the LASA community.
Draft programme for the event is available here: LASA Programme_2022
There is also a specific call for speakers for the LASA 3Rs session of the meeting. They are particularly interested in hearing about techniques which have been used to Replace animals as well as new 3Rs advances in Refinement and Reduction. Further information about the call is available here: LASA 3Rs_Section_-_Call_for_Speakers_2022